Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The efficacy of short-course blinatumomab immunotherapy as a bridge-to-HSCT in ph-negative B-cell acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

XSXiangqi ShaoLWLiping Wan

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows blinatumomab increases relapse-free survival in Ph-B-ALL, suggesting improved transplant outcomes.

Key Points

  • Blinatumomab led to higher 18-month rates of relapse-free survival compared to chemotherapy.
  • The 18-month relapse-free survival rate for blinatumomab treated patients was 78.5% versus 55% for chemotherapy.
  • Patients received blinatumomab for 14 days prior to undergoing hematopoietic stem cell transplantation.
  • Short-course blinatumomab reduced the incidence of chronic graft-versus-host disease after transplantation.

Cite This Study

Shao et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8b1https://doi.org/10.1182/blood-2025-6078
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Blinatumomab before and after allogeneic hematopoietic stem cell transplantation in adult patients with B-cell acute lymphoblastic leukemia2025
  2. 2Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity2025
  3. 3Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia2025 · 1 citations
  4. 4Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study2025
  5. 5Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab2025 · 1 citations